Affymax, Inc. (AFFY)
OTCMKTS
· Delayed Price · Currency is USD
0.0008
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST
Affymax Revenue
Affymax had revenue of $42.00K in the quarter ending June 30, 2014, a decrease of -92.00%. This brings the company's revenue in the last twelve months to $42.00K, down -99.86% year-over-year. In the year 2013, Affymax had annual revenue of $1.37M, down -98.55%.
Revenue (ttm)
42.00K
Revenue Growth
-99.86%
P/S Ratio
0.71
Revenue / Employee
21.00K
Employees
2
Market Cap
59.59K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2013 | 1.37M | -93.00M | -98.55% |
Dec 31, 2012 | 94.37M | 46.65M | 97.76% |
Dec 31, 2011 | 47.72M | -64.80M | -57.59% |
Dec 31, 2010 | 112.52M | -2.38M | -2.07% |
Dec 31, 2009 | 114.90M | 32.05M | 38.68% |
Dec 31, 2008 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Dec 31, 2005 | Pro | Pro | Pro |
Dec 31, 2004 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |